A Phase 3 interventional study of Placebo and Pregabalin in Fibromyalgia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 37 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-25.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing pregabalin in Fibromyalgia — 6 open to participants now, 6 under way, none of them phase 3. Pregabalin · Fibromyalgia.
Among the 30 studies testing pregabalin in Fibromyalgia, this one is the 7th largest by enrollment, is one of 3 that started in 2009, is one of 13 in phase 3, and was the 9th registered.
1,244 studies on the registry are indexed under Fibromyalgia; 255 are open to participants now.
Browse Fibromyalgia studies →6 of the 30 studies testing pregabalin in Fibromyalgia are open now, in 2 countries. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18–65
By country, each count listing its studies:
Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 160 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 14 · Phase 4 7
First in 2004; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 498 is above the median of 60 across 938 interventional studies indexed under Fibromyalgia.
Median enrollment 199 across the 30 interventional studies. Of the 22 that completed or were terminated, 10 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 30 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
19 studies in Fibromyalgia by Viatris Inc.: none open now, none under way, none of them phase 3. Of 19 finished, 13 (68%) have results posted.
Among the 19 studies in Fibromyalgia by Viatris Inc., this one is the 6th largest by enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2009, is one of 13 in phase 3, and was the 9th registered.
Viatris Inc.’s Fibromyalgia studies by the year they started, since 2004.
4 of the studies testing pregabalin in Fibromyalgia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07186751Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin Combined With Venlafaxine in Patients With Fibromyalgia | 2027-06-30 |
| NCT07230197Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin Combined With Dexmedetomidine in Patients With Fibromyalgia | 2027-06-30 |
| NCT07208357Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin Combined With Toludesvenlafaxine in Patients With Fibromyalgia | 2027-06-30 |
| NCT07171320Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin Combined With Desvenlafaxine in Patients With Fibromyalgia | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 30 studies testing pregabalin in Fibromyalgia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 19 in Fibromyalgia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study, will compare pregabalin with placebo for the duration of 15 weeks to evaluate the efficacy and safety of pregabalin in patients with fibromyalgia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Placebo
Drug: Pregabalin
Dosage: placebo, oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)
Dosage: 300 or 450 mg/day (150 or 225 mg bid), oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)
Change From Baseline for Numerical Rating Scale (NRS) Pain Scores at Endpoint-LOCF (Last Observation Carried Forward) Relative to Baseline
Change from baseline in mean NRS-Pain scores at endpoint-LOCF. Daily pain scores were assessed on an 11-point numerical rating scale \<(NRS)-Pain\> ranging from 0 (no pain) to 10 (worst possible pain).
Time frame: Baseline, Week 15 or study discontinuation
Percentage of Participants Who Was Categorized as "Improved (Very Much Improved, Much Improved, or a Minimally Improved)" According to the Patient Global Impressions of Change (PGIC)
PGIC was defined as participant rated instrument to measure participant's change in overall status on a 7-point scale; range from 1 (very much improved) to 7 (very much worse). Change was defined as a score of 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse) , 6 (much worse) or 7 (very much worse) on the scale.
Time frame: Week 15 or study discontinuation
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Sleep Disturbance
MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Sleep Disturbance subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of sleep disturbance. Change = mean scores at observation minus mean scores at baseline.
Time frame: Baseline, Week 15 or study discontinuation
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Snoring
MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Snoring subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of snoring. Change = mean scores at observation minus mean scores at baseline.
Time frame: Baseline, Week 15 or study discontinuation
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Awaken Short of Breath or With a Headache
MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Awaken Short of Breath or With a Headache subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of the symptom. Change = mean scores at observation minus mean scores at baseline.
Time frame: Baseline, Week 15 or study discontinuation
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Quantity of Sleep
MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Quantity of Sleep subscales rated 0 to 24 (number of hours slept). A higher score indicates greater quantity of sleep. Change = mean scores at observation minus mean scores at baseline.
Time frame: Baseline, Week 15 or study discontinuation
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Sleep Adequacy
MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Sleep Adequacy subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of sleep adequacy. Change = mean scores at observation minus mean scores at baseline.
Time frame: Baseline, Week 15 or study discontinuation
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Somnolence
MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Somnolence subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of somnolence. Change = mean scores at observation minus mean scores at baseline.
Time frame: Baseline, Week 15 or study discontinuation
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Overall Sleep Problems Index
MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Overall Sleep Problems Index subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of overall sleep problems. Change = mean scores at observation minus mean scores at baseline.
Time frame: Baseline, Week 15 or study discontinuation
Medical Outcomes Study (MOS) Sleep Scale - Number of Participants With Optimal Sleep at Endpoint
MOS-Sleep is a patient-rated questionnaire to assess sleep quality and quantity. Optimal sleep component is derived from Sleep Quantity average hours of sleep each night during the past 4 weeks. Optimal sleep was defined as sleep quantity of 7 or 8 hours per night.
Time frame: Week 15 or study discontinuation
Change From Baseline in Sleep Quality Score at Endpoint
Change: Mean sleep quality score at endpoint minus mean at baseline. Sleep quality scores range from 0-10 with higher scores indicating decreased sleep quality.
Time frame: Baseline, Week 15 or study discontinuation
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Total Scores
FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.
Time frame: Baseline, Week 15 or study discontinuation
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Physical Function
FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.
Time frame: Baseline, Week 15 or study discontinuation
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Feel Good
FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.
Time frame: Baseline, Week 15 or study discontinuation
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Work Miss
FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.
Time frame: Baseline, Week 15 or study discontinuation
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Housework
FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.
Time frame: Baseline, Week 15 or study discontinuation
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Pain
FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.
Time frame: Baseline, Week 15 or study discontinuation
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Tiredness
FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.
Time frame: Baseline, Week 15 or study discontinuation
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Morning
FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.
Time frame: Baseline, Week 15 or study discontinuation
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Stiffness
FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.
Time frame: Baseline, Week 15 or study discontinuation
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Anxious
FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.
Time frame: Baseline, Week 15 or study discontinuation
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Depression
FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.
Time frame: Baseline, Week 15 or study discontinuation
Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Physical Functioning
Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.
Time frame: Baseline, Week 15 or study discontinuation
Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Role Limitations-Physical
Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.
Time frame: Baseline, Week 15 or study discontinuation
Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Bodily Pain
Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.
Time frame: Baseline, Week 15 or study discontinuation
Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- General Health Perception
Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.
Time frame: Baseline, Week 15 or study discontinuation
Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Social Functioning
Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.
Time frame: Baseline, Week 15 or study discontinuation
Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Role Limitations-Emotional
Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.
Time frame: Baseline, Week 15 or study discontinuation
Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Vitality
Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.
Time frame: Baseline, Week 15 or study discontinuation
Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Mental Health
Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.
Time frame: Baseline, Week 15 or study discontinuation
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) - Anxiety
Change: Mean HADS score at observation minus Mean at baseline. HADS anxiety and depression subscale scores range from 0 to 21, with higher scores indicating greater severity of the subscale condition.
Time frame: Baseline, Week 15 or study discontinuation
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) - Depression
Change: Mean HADS score at observation minus Mean at baseline. HADS anxiety and depression subscale scores range from 0 to 21, with higher scores indicating greater severity of the subscale condition.
Time frame: Baseline, Week 15 or study discontinuation
Change From Baseline in Pain Visual Analog Scale (Pain VAS) Score at Endpoint
The pain VAS is a horizontal line; 100 mm in length, self-administered by the patient to rate pain from 0 (no pain) to 100 (worst possible pain). The score indicates the pain intensity during the past 1 week before a visit. Change = mean scores at observation minus mean scores at baseline.
Time frame: Baseline, Week 15 or study discontinuation
| Milestone | Placebo | Pregabalin |
|---|---|---|
| Started | 248 | 250 |
| Completed | 208 | 207 |
| Not completed | 40 | 43 |
| Withdrew: Lack of efficacy | 26 | 10 |
| Withdrew: Adverse event | 8 | 24 |
| Withdrew: Not meeting entrance criteria | 2 | 5 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Other | 2 | 2 |
Change from baseline in mean NRS-Pain scores at endpoint-LOCF. Daily pain scores were assessed on an 11-point numerical rating scale \<(NRS)-Pain\> ranging from 0 (no pain) to 10 (worst possible pain).
| Scores on a scale | Placebo | Pregabalin |
|---|---|---|
| Change From Baseline for Numerical Rating Scale (NRS) Pain Scores at Endpoint-LOCF (Last Observation Carried Forward) Relative to Baseline | -1.03 ± 0.12 | -1.48 ± 0.12 |
PGIC was defined as participant rated instrument to measure participant's change in overall status on a 7-point scale; range from 1 (very much improved) to 7 (very much worse). Change was defined as a score of 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse) , 6 (much worse) or 7 (very much worse) on the scale.
| Percentage of participants | Placebo | Pregabalin |
|---|---|---|
| Percentage of Participants Who Was Categorized as "Improved (Very Much Improved, Much Improved, or a Minimally Improved)" According to the Patient Global Impressions of Change (PGIC) | 62.1 | 70.0 |
MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Sleep Disturbance subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of sleep disturbance. Change = mean scores at observation minus mean scores at baseline.
| Scores on a scale | Placebo | Pregabalin |
|---|---|---|
| Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Sleep Disturbance | -8.13 ± 1.31 | -17.62 ± 1.31 |
MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Snoring subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of snoring. Change = mean scores at observation minus mean scores at baseline.
| Scores on a scale | Placebo | Pregabalin |
|---|---|---|
| Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Snoring | -1.61 ± 1.33 | 3.37 ± 1.33 |
MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Awaken Short of Breath or With a Headache subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of the symptom. Change = mean scores at observation minus mean scores at baseline.
| Scores on a scale | Placebo | Pregabalin |
|---|---|---|
| Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Awaken Short of Breath or With a Headache | -3.02 ± 1.36 | -8.01 ± 1.36 |
MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Quantity of Sleep subscales rated 0 to 24 (number of hours slept). A higher score indicates greater quantity of sleep. Change = mean scores at observation minus mean scores at baseline.
| Scores on a scale | Placebo | Pregabalin |
|---|---|---|
| Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Quantity of Sleep | 0.17 ± 0.06 | 0.46 ± 0.06 |
MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Sleep Adequacy subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of sleep adequacy. Change = mean scores at observation minus mean scores at baseline.
| Scores on a scale | Placebo | Pregabalin |
|---|---|---|
| Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Sleep Adequacy | 8.02 ± 1.41 | 15.50 ± 1.40 |
MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Somnolence subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of somnolence. Change = mean scores at observation minus mean scores at baseline.
| Scores on a scale | Placebo | Pregabalin |
|---|---|---|
| Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Somnolence | -4.66 ± 1.29 | 6.65 ± 1.28 |
MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Overall Sleep Problems Index subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of overall sleep problems. Change = mean scores at observation minus mean scores at baseline.
| Scores on a scale | Placebo | Pregabalin |
|---|---|---|
| Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Overall Sleep Problems Index | -7.07 ± 0.96 | -10.06 ± 0.95 |
MOS-Sleep is a patient-rated questionnaire to assess sleep quality and quantity. Optimal sleep component is derived from Sleep Quantity average hours of sleep each night during the past 4 weeks. Optimal sleep was defined as sleep quantity of 7 or 8 hours per night.
| Participants | Placebo | Pregabalin |
|---|---|---|
| Medical Outcomes Study (MOS) Sleep Scale - Number of Participants With Optimal Sleep at Endpoint | 53 | 71 |
Change: Mean sleep quality score at endpoint minus mean at baseline. Sleep quality scores range from 0-10 with higher scores indicating decreased sleep quality.
| Scores on a scale | Placebo | Pregabalin |
|---|---|---|
| Change From Baseline in Sleep Quality Score at Endpoint | -0.79 ± 0.12 | -1.52 ± 0.12 |
FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.
| Scores on a scale | Placebo | Pregabalin |
|---|---|---|
| Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Total Scores | -7.26 ± 1.08 | -10.59 ± 1.07 |
FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.
| Scores on a scale | Placebo | Pregabalin |
|---|---|---|
| Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Physical Function | -0.19 ± 0.11 | -0.47 ± 0.11 |
FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.
| Scores on a scale | Placebo | Pregabalin |
|---|---|---|
| Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Feel Good | -0.82 ± 0.17 | -1.45 ± 0.17 |
FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.
| Scores on a scale | Placebo | Pregabalin |
|---|---|---|
| Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Work Miss | -0.30 ± 0.15 | -0.31 ± 0.15 |
FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.
| Scores on a scale | Placebo | Pregabalin |
|---|---|---|
| Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Housework | -1.00 ± 0.15 | -1.32 ± 0.15 |
FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.
| Scores on a scale | Placebo | Pregabalin |
|---|---|---|
| Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Pain | -1.06 ± 0.15 | -1.46 ± 0.15 |
FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.
| Scores on a scale | Placebo | Pregabalin |
|---|---|---|
| Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Tiredness | -0.94 ± 0.14 | -1.43 ± 0.14 |
FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.
| Scores on a scale | Placebo | Pregabalin |
|---|---|---|
| Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Morning | -0.97 ± 0.15 | -1.56 ± 0.15 |
FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.
| Scores on a scale | Placebo | Pregabalin |
|---|---|---|
| Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Stiffness | -0.90 ± 0.15 | -1.05 ± 0.15 |
FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.
| Scores on a scale | Placebo | Pregabalin |
|---|---|---|
| Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Anxious | -0.64 ± 0.16 | -0.92 ± 0.16 |
FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.
| Scores on a scale | Placebo | Pregabalin |
|---|---|---|
| Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Depression | -0.51 ± 0.14 | -0.55 ± 0.14 |
Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.
| Scores on a scale | Placebo | Pregabalin |
|---|---|---|
| Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Physical Functioning | 4.72 ± 0.93 | 9.01 ± 0.93 |
Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.
| Scores on a scale | Placebo | Pregabalin |
|---|---|---|
| Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Role Limitations-Physical | 8.36 ± 1.30 | 10.04 ± 1.30 |
Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.
| Scores on a scale | Placebo | Pregabalin |
|---|---|---|
| Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Bodily Pain | 9.50 ± 1.06 | 11.65 ± 1.06 |
Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.
| Scores on a scale | Placebo | Pregabalin |
|---|---|---|
| Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- General Health Perception | 2.83 ± 0.85 | 4.66 ± 0.85 |
Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.
| Scores on a scale | Placebo | Pregabalin |
|---|---|---|
| Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Social Functioning | 6.84 ± 1.38 | 8.43 ± 1.37 |
Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.
| Scores on a scale | Placebo | Pregabalin |
|---|---|---|
| Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Role Limitations-Emotional | 3.50 ± 1.36 | 3.27 ± 1.35 |
Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.
| Scores on a scale | Placebo | Pregabalin |
|---|---|---|
| Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Vitality | 5.12 ± 1.22 | 9.53 ± 1.21 |
Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.
| Scores on a scale | Placebo | Pregabalin |
|---|---|---|
| Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Mental Health | 3.33 ± 0.98 | 5.97 ± 0.98 |
Change: Mean HADS score at observation minus Mean at baseline. HADS anxiety and depression subscale scores range from 0 to 21, with higher scores indicating greater severity of the subscale condition.
| Scores on a scale | Placebo | Pregabalin |
|---|---|---|
| Change From Baseline in Hospital Anxiety and Depression Scale (HADS) - Anxiety | -0.09 ± 0.18 | -0.57 ± 0.18 |
Change: Mean HADS score at observation minus Mean at baseline. HADS anxiety and depression subscale scores range from 0 to 21, with higher scores indicating greater severity of the subscale condition.
| Scores on a scale | Placebo | Pregabalin |
|---|---|---|
| Change From Baseline in Hospital Anxiety and Depression Scale (HADS) - Depression | 0.00 ± 0.20 | -0.29 ± 0.20 |
The pain VAS is a horizontal line; 100 mm in length, self-administered by the patient to rate pain from 0 (no pain) to 100 (worst possible pain). The score indicates the pain intensity during the past 1 week before a visit. Change = mean scores at observation minus mean scores at baseline.
| Scores on a scale | Placebo | Pregabalin |
|---|---|---|
| Change From Baseline in Pain Visual Analog Scale (Pain VAS) Score at Endpoint | -14.11 ± 1.45 | -20.30 ± 1.44 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/248 (0%) | 113/248 (45.6%) |
| Pregabalin | — | 1/250 (0.4%) | 195/250 (78%) |
| Event | Placebo | Pregabalin |
|---|---|---|
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/248 | 1/250 |
| Event | Placebo | Pregabalin |
|---|---|---|
| SomnolenceNervous system disorders | 45/248 | 116/250 |
| DizzinessNervous system disorders | 15/248 | 74/250 |
| NasopharyngitisInfections and infestations | 45/248 | 45/250 |
| Weight increasedInvestigations | 9/248 | 39/250 |
| ConstipationGastrointestinal disorders | 17/248 | 36/250 |
| Feeling abnormalGeneral disorders | 3/248 | 20/250 |
| Oedema peripheralGeneral disorders | 3/248 | 18/250 |
| HeadacheNervous system disorders | 15/248 | 15/250 |
| Vision blurredEye disorders | 3/248 | 13/250 |
| Age, Customized(Participants) | Placebo | Pregabalin | Total |
|---|---|---|---|
| <18 years | 0 | 0 | 0 |
| Between 18 years and 44 years | 104 | 101 | 205 |
| Between 45 years and 64 years | 123 | 125 | 248 |
| >=65 years | 21 | 24 | 45 |
| Sex: Female, Male(Participants) | Placebo | Pregabalin | Total |
|---|---|---|---|
| Female | 217 | 226 | 443 |
| Male | 31 | 24 | 55 |
The record gives a start of Mar 2009, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2012, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →